International review of neurobiology
2025
Severin B Vogt, Matthias E. Liechti
1 citation
To design therapeutic trials and select the most appropriate substance and dose for an indication, a detailed understanding of clinical pharmacology is crucial. In recent years, several studies have explored the human pharmacology of different psychedelics and 3,4-methylendioxymethylamphetamin (MDMA). This chapter summarizes pharmacological characteristics of the serotonergic psychedelics...
Progress in Brain Research
2025
Mohamad Alfateh Abou Haykal
This chapter explores the profound impact of love and joyful memories on the brainstem, emphasizing their significance for mental and emotional well-being. It introduces the brainstem's role in essential life functions and its connection to higher emotional processes. Topics delve into the neurobiology of love, detailing how chemicals like oxytocin, dopamine, and serotonin interact with...
Frontiers in Pharmacology
2025
Sarah Delcourte, Amel Bouloufa, Renaud Rovera et al.
3 citations
Beside image vision, light plays a pivotal role in regulating diverse non-visual functions, including affective behaviors. Recently, bright light stimulation (BLS) was revealed to be beneficial for treating non-seasonal depression, although its mechanism of action is not fully understood. We developed a novel mouse model of refractory depression, induced through social isolation and chronic...
Molecular biotechnology
2025
Fatima Iftikhar Shah, Somia Shehzadi, Fatima Akram et al.
2 citations
Depression, a global health concern with significant implications for suicide rates, remains challenging to treat effectively with conventional pharmacological options. The existing pharmaceutical interventions for these illnesses need daily dosing, are accompanied by various adverse effects, and may exhibit limited efficacy in certain cases. However, hope emerges from an unlikely...
Neuropharmacology
2025
James J Gattuso, Carey Wilson, Anthony J. Hannan et al.
10 citations
Psilocybin is a serotonergic psychedelic compound which shows promise for treating compulsive behaviours. This is particularly pertinent as compulsive disorders require research into new pharmacological treatment options as the current frontline treatments such as selective serotonin reuptake inhibitors, require chronic administration, have significant side effects, and leave almost half of the...
American Journal of Psychiatry
2025
Johannes G. Ramaekers, Johannes T. Reckweg, Natasha L. Mason
25 citations
Unlike classical antidepressants, psychedelics such as psilocybin have been shown to induce a rapid antidepressant response. In the wake of this development, interest has emerged in ultra-fast, short-acting psychedelics such as 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) and N,N-dimethyltryptamine (DMT) with the expectation that these can produce rapid antidepressant effects following an...
Progress in Neuro-Psychopharmacology and Biological Psychiatry
2025
Ines Erkizia-Santamaría, Igor Horrillo, J. Javier Meana et al.
10 citations
In the rapidly growing field of psychedelic research, psilocybin (and active metabolite psilocin) has been proposed as a promising candidate in the search for novel treatments for neuropsychiatric disorders. Clinical trials have revealed that psilocybin has a large, rapid, and persistent effect in the improvement of symptoms of depression and anxiety. The safety profile is considered...
Neuropsychiatric Disease and Treatment
2025
Daniel A Kinderlehrer
13 citations
The incidence of mental health disorders is increasing worldwide. While there are multiple factors contributing to this problem, neuroinflammation underlies a significant subset of psychiatric conditions, particularly major depressive and anxiety disorders. Anti-inflammatory interventions have demonstrated benefit in these conditions. Psilocin, the active ingredient of mushrooms in the...
Neuroscience of Consciousness
2025
Adam Safron, Arthur Juliani, Nicco Reggente et al.
44 citations
How is it that psychedelics so profoundly impact brain and mind? According to the model of "Relaxed Beliefs Under Psychedelics" (REBUS), 5-HT2a agonism is thought to help relax prior expectations, thus making room for new perspectives and patterns. Here, we introduce an alternative (but largely compatible) perspective, proposing that REBUS effects may primarily correspond to a particular (but...
Current Topics in Behavioral Neurosciences
December 31, 2024
Mazdak M. Bradberry, Paul S. Appelbaum, Natalie Gukasyan
7 citations
Humans have long used classical serotonergic psychedelics, such as psilocybin, for a variety of purposes. Entactogens, such as methylenedioxymethamphetamine (MDMA), emerged during the twentieth century and have likewise seen use in a broad range of settings. Interest has arisen in the use of classical psychedelics and entactogens, together termed "psychedelics," for therapeutic purposes in...